Pfizer to ax up to 8% of R&D staff

Drugmaker preparing to cut up to 800 researcher jobs; 'prioritizing' drug development for cancer, Alzheimer's and pain management.

EMAIL  |   PRINT  |   SHARE  |   RSS
 
google my aol my msn my yahoo! netvibes
Paste this link into your favorite RSS desktop reader
See all CNNMoney.com RSS FEEDS (close)
By Aaron Smith, CNNMoney.com staff writer

NEW YORK (CNNMoney.com) -- The pharma giant Pfizer said it is cutting up to 8% of its research staff.

New York-based Pfizer (PFE, Fortune 500), the leading seller of pharmaceuticals, said on Tuesday that it is reducing research jobs by 5% to 8% worldwide, which could total 800 job reductions.

The company's stock was up less than 1% following the news.

Pfizer spokesman Raymond Kerins said this is part of the company's plan to "raise productivity."

"We're being really methodical about how we're staffing our people so that we can assure we have the right scientific expertise for the future to make sure we can achieve all our goals," said Kerins.

Kerins said company is "prioritizing" the development of drugs and potential treatments for cancer, Alzheimer's and pain, Kerins said. This will include a focus in bringing late-stage pipeline drugs to market, he said.

Also, Kerins said Pfizer aims to be "top tier" in the biotech industry, and the company will "pursue the best science externally through partnerships, licensing and M&A." He said this is all part of Pfizer's "overhaul plan," implemented by Martin Mackay when he took over research and development about one and a half years ago.

"R&D is the lifeblood of pharma but Pfizer has not been that productive," said Les Funtleyder, pharma analyst for Miller Tabak. "So it may be a case that they are trying to eliminate non-productive assets.

He added, "I would imagine the scientists would say the problem is with management."

Tony Butler, pharma analyst for Barclays Capital, said Pfizer has already shed some 13,000 jobs since 2007, down to the estimated level of about 87,000 staffers.

Butler said that Pfizer can probably afford to trim its R&D staff, because it spends more on research than any of its competitors. He estimated that the company spent about $7.5 billion on R&D in 2008.

The drugmaker is scheduled to release its fourth-quarter earnings results on Jan. 28. The company is expected to report a 3% decline in revenue to $12.6 billion, compared to the year before, according to a consensus of analysts from Thomson Reuters.

The company is also expected to report a 14% increase in earnings per share, to 60 cents, compared to the year-ago, according to Thomson Reuters.

How do you think Barack Obama's presidency will affect you and your wallet? What can he do to help you - and others - in these trying economic times? E-mail us at realstories@cnnmoney.com, and your thoughts could be part of an upcoming story.  To top of page

Features
They're hiring!These Fortune 100 employers have at least 350 openings each. What are they looking for in a new hire? More
If the Fortune 500 were a country...It would be the world's second-biggest economy. See how big companies' sales stack up against GDP over the past decade. More
Sponsored By:
More Galleries
5 ways retailers are tracking you If you think pesky salespeople are invading your personal space, check out these 5 technologies that are tracking your movements throughout a store. More
Moto X vs. Droid Turbo: Which Droid should you buy? Motorola has made the two best Android smartphones this year. Here's how they stack up. More
My part-time job is a dead end, but it's all I can find CNNMoney profiles 4 of America's 7 million part-time workers unable to find full-time jobs. More

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2014 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2014. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2014 and/or its affiliates.